Funder: addenbrooke's charitable trust, cambridge university hospital

Barrans, Sharon

Chng, Wee Joo

Du, Ming Qing

Follows, George

Goh, Yeow Tee

Gong, Chun

Grigoropoulos, Nicholas Francis

Hodson, Daniel J

Huang, Dachuan

Kizhakeyil, Atish

Lim, Jing Quan

Lim, Soon Thye

Loh, Xinpeng

Low, Zun Siong

Lu, Pang Wan

Nagarajan, Chandramouli

Ng, Aik Seng

Ong, Choon Kiat

Poh, Zhi Sheng

Prasannan, Praseetha

Tan, Michelle Guet Khim

Tan, Suat Hoon

Verma, Navin Kumar

Wong, Brandon Han Siang

Zaini, Nurmahirah Binte Mohammed

Molecular Cancer

English

Funder: addenbrooke's charitable trust, cambridge university hospitals; doi: http://dx.doi.org/10.13039/50110000292

Hodson, Daniel J.

Apollo (Cambridge)

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Atish Kizhakeyil

Nurmahirah Binte Mohammed Zaini

Zhi Sheng Poh

Brandon Han Siang Wong

Xinpeng Loh

Aik Seng Ng

Zun Siong Low

Praseetha Prasannan

Chun Gong

Michelle Guet Khim Tan

Chandramouli Nagarajan

Dachuan Huang

Pang Wan Lu

Jing Quan Lim

Sharon Barrans

Choon Kiat Ong

Soon Thye Lim

Wee Joo Chng

George Follows

Daniel J. Hodson

Ming Qing Du

Yeow Tee Goh

Suat Hoon Tan

Nicholas Francis Grigoropoulos

Navin Kumar Verma

Directory of Open Access Journals

Oxford University Research Archive

Non-Hodgkin a diverse group of malignancies, encompassing the common difuse large B-cell lymphoma
(DLBCL) to the rarer T-cell lymphomas. Chemoresistance is a major barrier to treatment and the mechanisms
through which it occurs are incompletely understood
[1]. Although eforts are made to target frequently dysregulated pathways in NHL subtypes, these diseases still
evolve into aggressive forms resistant even to newer therapies [2].This research was supported, in part, by Start-Up Grant to NKV provided
by Lee Kong Chian School of Medicine, Nanyang Technological University
Singapore (L0412290), the Singapore Ministry of Education (MOE) under its
MOE Academic Research Fund (AcRF) Tier 2 Grant (MOE2017-T2–2-004), and
the National Research Foundation Singapore under its Open Fund Large
Collaborative Grant (OFLCG18May-0028) and administered by the Singapore
Ministry of Health’s National Medical Research Council (NMRC). N.F.G.
acknowledges funding support from the Singapore Ministry of Health’s
National Medical Research Council under its NMRC of Singapore Transition
Award (NMRC/TA/0051/2016), Kay Kendall Leukaemia Fund Junior Clinical
Research Training Fellowship (KKL649) and the Addenbrooke’s Charitable
Trust Research Training Fellowship. D.H. was supported by the Medical
Research Council (MR/M008584/1) and Blood Cancer UK and receives core
funding from Wellcome (203151/Z/16/Z) and MRC to the Wellcome-MRC
Cambridge Stem Cell Institute and from the CRUK Cambridge Centre
(A25117). A.K. and Z.S.P. were provided with PhD fellowship by Lee Kong
Chian School of Medicine, Nanyang Technological University Singapore.
B.H.S.W. was provided with PhD fellowship by HealthTech NTU, Nanyang
Technological University Singapore

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.

10.1186/s12943-021-01437-0MOLECULAR CANCER20

ScholarBank@NUS

https://www.repository.cam.ac.uk/bitstream/1810/330848/2/article.pdf

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.

Abstract

Similar works

Full text

Available Versions

Apollo (Cambridge)

Directory of Open Access Journals

Oxford University Research Archive

Apollo (Cambridge)

Apollo (Cambridge)

ScholarBank@NUS